Company: HURA
Filing Date: 2025-04-01
Form Type: 425
Source: 0001193125-25-069713
Chunk: 9

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-04-01
Form: 425
Chunk 9
---
 trial |

| • |     | Q3: Initiate checkpoint inhibitor resistant metastatic cancer “basket” trial |

| • |     | IFx-3.0 |

| • |     | Q4: Advance characterization toward lead compound selection |

| • |     | VISTA Inhibiting mAb |

| • |     | Q2: Target closing of Kineta acquisition |

| • |     | Q2: Phase 1 VISTA inhibitor +/- pembrolizumab results |

| • |     | Q4: Initiate Phase 2 trial VISTA trial in NPM1 mutated AML |

| • |     | Novel bi-specific non-tumor                                              
 targeting immune modulating Antibody Drug or Antibody Peptide Conjugates |

| • |     | Advance delta opioid receptor technology platform |

| • |     | Presentations at key scientific meetings |

Summary of Financial Results for the Full Year 2024 Research and development (R&D) expense was $13.3 million and $9.4 million for the years ended December 31, 2024 and 2023, respectively. The increase in R&D of $3.9 million is mainly related to:

| • |     | an increase of approximately $1.6 million due to ongoing clinical development of IFx-2.0; |

| • |     | an increase of approximately $0.4 million due to preclinical research of 
 IFx-3.0 and MDSCs; and                                                   |

| • |     | an increase of approximately $1.9 million in salary and personnel related costs. |

General and administrative (G&A) expenses were $4.3 million and $4.1 million for the years ended December 31, 2024 and 2023, respectively. The increase in G&A of $0.2 million was mainly attributable to increases in non-cashstock compensation expense and costs associated with being a public company incurred in 2024 offset by decrease in legal fees associated with the subsequently terminated proposed merger with CohBar, Inc. which were incurred in 2023.

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired
resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuH